CROSS

NTR487 📎

Regimen

Experimental
neoadjuvant carboplatin + paclitaxel + 41.4 Gy RT + surgery
Control
surgery alone

Population

Resectable esophageal or esophagogastric junction cancer (75% adenocarcinoma, 23% SCC)

Key finding

Median OS 49.4 vs 24.0 mo (HR 0.657, 95% CI 0.495-0.871, P=0.003); R0 92% vs 69%; pCR 29%. In-hospital mortality 4% both arms.

Source: PMID 22646630

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.38)